Response to influenza virus vaccination in patients immunocompromised due to chemotherapy

Recruiting

• Conditions: breast cancer.; Mamma carcinoma; 10047438; 10006291

• Registration Number: NL-OMON33424
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 385

Inclusion Criteria

1.Patients with mamma carcinoma treated with FEC-containing triweekly chemotherapy at moment of vaccination
2.Patients with heart failure and therefore having an indication for the influenza vaccination
3.Age >= 18 years
4.Signing of informed consent

Exclusion Criteria

1.Fever at time of vaccination defined as a temperature of >= 38.5 °C.
2.Previous/known allergic reaction to any of the components of the vaccines given, for example hypersensitivity to egg protein
3.Thrombocytopenia (defined as < 50 x 10*9/L ) at moment of vaccination
4.Treatment with prednisolone on moment of vaccination.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p> adequate rise in antibody titre against the influenza virus </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>·Antibody titres against the influenza virus before and after vaccination</p><br>